Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 5, 2018
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
[ Fri, Jan 05th 2018
] - WOPRAI
Thu, January 4, 2018
[ Thu, Jan 04th 2018
] - WOPRAI
[ Thu, Jan 04th 2018
] - WOPRAI
[ Thu, Jan 04th 2018
] - WOPRAI
[ Thu, Jan 04th 2018
] - WOPRAI
Yun Zhong Initiated (SRPT) at Strong Buy and Held Target at $75 on, Jan 4th, 2018
Yun Zhong of Janney Montgomery Scott, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy and Held Target at $75 on, Jan 4th, 2018.
Yun has made no other calls on SRPT in the last 4 months.
There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 1 agrees with Yun's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Gena Wang of "Barclays" Maintained at Hold with Increased Target to $49 on, Thursday, October 26th, 2017
These are the ratings of the 3 analyists that currently disagree with Yun
- Debjit Chattopadhyay of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $75 on, Friday, December 1st, 2017
- Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Monday, October 2nd, 2017
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $81 on, Thursday, September 7th, 2017
